Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06018766Phase 2Recruiting

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

Role: collaborator

NCT05798923Phase 2Active Not Recruiting

A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension

Role: lead

NCT05163886Phase 2Completed

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

Role: lead

NCT02594384Phase 1Completed

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Role: lead

NCT03426605Phase 1Completed

A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Role: lead

NCT04446377Phase 2Completed

A Study of LAM-002A for the Prevention of Progression of COVID-19

Role: lead

NCT05483322Unknown

An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)

Role: lead

All 7 trials loaded